Brimonidine
- TRADE NAMES: Alphagan P (Allergan); Mirvaso (Galderma)
- INDICATIONS: Open-angle glaucoma, ocular hypertension; topical application for rosacea
- CLASS: Adrenergic alpha2-receptor agonist
- HALF-LIFE: 12 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Amitriptyline, MAO inhibitors, Tricyclic antidepressants
PREGNANCY CATEGORY: B
[T] = Topical
Please login to see the rest of this drug profile
SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RESPIRATORY.
OTHER.
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of brimonidine in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 07/31/2023
Symbol key
Incidence
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric